Canakinumab, which is a monoclonal antibody targeting IL-1β, provides an effective alternative for managing febrile attacks in these resistant cases, even in the absence of certain genetic markers associated with FMF [21]. The gene discussed is IL1B; the disease is familial Mediterranean fever.